News | October 21, 2024

SMC Pharma Services Enters Autoinjector Development Agreement With A Biopharmaceutical Company For The Bios Platform

Source: SMC Ltd.

Somerset, Wisconsin – SMC Pharma Services has entered into a development agreement with a commercial stage biopharmaceutical company specializing in care for genetic rare diseases to develop an autoinjector platform solution for a clinical trial in 2026. The strategic partnership includes development and commercialization of the combination product in SMC’s proprietary Bios autoinjector platform.

The Bios autoinjector platform is designed to address the evolving needs of the market offering a flexible and powerful solution for delivering injections of varying volumes and viscosities. With the ability to accommodate injection volumes up to 5ml and high-viscosity fluids of up to 1000cP, the platform is built to handle the increasing demands for larger injection sizes and fast delivery times with viscus fluids. A modular design ensures flexibility, minimizing the need for change parts while supporting a wide range of syringe geometries. A key innovation is the use of a gas-powered engine, which generates operational forces up to 1000N, making it more powerful and compact than traditional spring-driven systems. This advanced force management system ensures safe and reliable injections even under high-stress conditions. By addressing key challenges such as device size, patient comfort, and syringe compatibility, the Bios platform offers a robust, market-aligned solution capable of supporting a broad spectrum of drug delivery applications.

“The agreement recognizes the Bios platform solution built around extended functionality whilst retaining a compact and versatile format. Platform benefits include a self-administration enabling design, flexible, configurable and built around ISO standard staked needle syringes. The platform offers a great solution for biotherapies. We are delighted we can make a real difference to the patients. Our work continues in this space to bring platform solutions that are patient-centric, able to deliver complex therapies and offer sustainable solutions.” said Uri Baruch, GM of SMC’s Pharma Services division.

With over 35+ years in the Healthcare industry and global GMP manufacturing sites, SMC provides “end-to-end” services including drug product development, device design and development, sterile manufacturing, device assembly and final packaging. SMC is committed to bringing complete solutions to pharmaceutical customers. Chetan N. Patel, Owner and CEO of SMC Ltd. and SMC Pharma Services Ltd., has a strategic vision for the Company, “This marks yet another successful milestone for SMC as we embark on pharmaceutical partnerships providing drug delivery solutions for advancing therapies focused on patient benefits and unmet therapeutic needs”.

Forward looking statements: SMC Ltd.

The press release contains forward looking statements based on current outlook, scope of work and plans. Such forward looking statements cannot be guaranteed due to uncertainties. SMC is providing this information as of this date and has disclaimer for any responsibility to update in the future, to confirm or change in its future discourse.

About SMC Ltd.

SMC Ltd. is a global contract manufacturer offering complete design, molding services, and finished devices for the medical, diagnostic and pharmaceutical industries. With locations in Wisconsin, Ohio, Massachusetts, North Carolina, California, Costa Rica, United Kingdom, and India, SMC’s facilities provide over one million sq. ft. dedicated to high and low volume medical manufacturing. The Company’s medical operations offer ISO 13485 quality systems, white room, class 7 and 8 clean rooms with services including design, engineering, project management, and validation. Integrated capabilities include thermoplastic molding (including 2-shot), LIM (liquid injection molding), secondary operations, micro molding, assembly, fill-finish capabilities, and kitting and packaging of finished devices. www.smcltd.com

Source: SMC Ltd.